Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rare blood disease

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

Roche's Perjeta pertuzumab

Roche’s Perjeta should be ‘new standard’ in breast cancer

Could improve survival when added to therapy with Herceptin and docetaxel

- PMLiVE

Roche’s Julie Warner joins Boyds

She takes up appointment as an associate director at the drug development consultancy

Roche - Basel

Roche moves eye drug lampalizumab into phase III

It could be the first treatment for geographic atrophy

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

Roche - Basel

Roche wins early use RA approval for RoActemra in Europe

Adds to existing indications in arthritis and Castleman’s disease

- PMLiVE

Levinson resigns from Roche board

Declares conflict of interest due to his position as CEO at Calico

- PMLiVE

Alexion convinces NICE of Soliris’ value

But recommendation of the expensive 'ultra orphan' drug' comes with conditions

- PMLiVE

Diagnostics are rising up the pharma value chain

Pharma interview: Anssi Pulkkinen from Roche Diagnostics, Finland on the increasing prominence of diagnostics

Roche - Basel

Roche boosts respiratory presence with InterMune purchase

Deal is fourth takeover in three months for Swiss pharma company

- PMLiVE

Chugai soars on Roche buyout rumours

Reports circulating that Swiss company is poised to make $10bn offer

- PMLiVE

Avastin gets US green light for late-stage cervical cancer

Fifth oncology indication for Roche’s medicine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links